Patents by Inventor Julian Davies
Julian Davies has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20160125759Abstract: Provided herein are various conditioned response toilet training systems and methods. The various embodiments described herein include components for detecting elimination events reliably and quickly; notifying caregivers of these elimination events; conditioning children such that a specific cue or set of cues becomes associated with the act of elimination; training one or more caregivers to learn the behavioral antecedents and overall elimination patterns of the child; predicting elimination events so that caregivers may be prospectively notified of a likely elimination; and training children to communicate their elimination needs to caregivers.Type: ApplicationFiled: October 29, 2015Publication date: May 5, 2016Inventors: Adam Michael DOUGHERTY, Julian DAVIES
-
Patent number: 9260531Abstract: The present invention relates to antibodies, or antigen-binding fragments thereof, that bind to the extracellular domain of human c-Met, compositions and kits comprising such c-Met antibodies, or antigen-binding fragments thereof, and methods of using the same for detection of human c-Met that aid in identifying patients with tumors expressing or overexpressing human Met and/or improving their treatment response with anti-c-Met therapeutics.Type: GrantFiled: May 1, 2013Date of Patent: February 16, 2016Assignee: Eli Lilly and CompanyInventors: Gregory Beuerlein, Julian Davies, Irene Jennifer Denning, Ling Liu, Jirong Lu, Peter Edward Vaillancourt
-
Patent number: 9201074Abstract: Provided is a monoclonal antibody, or antigen-binding fragment thereof, that binds to c-Met. Such antibodies, or antigen-binding fragments thereof, are useful in in vivo, ex vivo or in vitro immunochemical and other imaging methods for detecting cell surface c-Met receptor levels for diagnostic, prognostic and predictive purposes, and for optimizing therapeutic regimens in patients harboring tumors in which c-Met is implicated in pathogenesis.Type: GrantFiled: September 13, 2012Date of Patent: December 1, 2015Assignee: Eli Lilly and CompanyInventors: Julian Davies, Ling Liu, Jirong Lu
-
Publication number: 20150266954Abstract: The invention relates to engineered, humanized antibodies that have high binding affinity for and neutralize human IL-21, methods of using the antibodies to treat conditions in which antagonism or neutralization of the effects of IL-21 is warranted, such as autoimmune conditions, compositions and methods for recombinantly producing the antibodies, and pharmaceutical compositions comprising the antibodies.Type: ApplicationFiled: March 13, 2015Publication date: September 24, 2015Inventors: Julian Davies, Fabio Magrini, Andrea Paula Martin, Neelufar Mozaffarian, Chetankumar N. Patel, Oliver Schroeder
-
Publication number: 20150118238Abstract: The present invention relates to antibodies, or antigen-binding fragments thereof, that bind to the extracellular domain of human c-Met, compositions and kits comprising such c-Met antibodies, or antigen-binding fragments thereof, and methods of using the same for detection of human c-Met that aid in identifying patients with tumors expressing or overexpressing human Met and/or improving their treatment response with anti-c-Met therapeutics.Type: ApplicationFiled: May 1, 2013Publication date: April 30, 2015Inventors: Gregory Beuerlein, Julian Davies, Irene Jennifer Denning, Ling Liu, Jirong Lu, Peter Edward Vaillancourt
-
Publication number: 20140349310Abstract: Provided is a monoclonal antibody, or antigen-binding fragment thereof that binds to c-Met. Such antibodies, or antigen-binding fragments thereof, are useful in in vivo, ex vivo or in vitro immunochemical and other imaging methods for detecting cell surface c-Met receptor levels for diagnostic, prognostic and predictive purposes, and for optimizing therapeutic regimens in patients harboring tumors in which c-Met is implicated in pathogenesis.Type: ApplicationFiled: September 13, 2012Publication date: November 27, 2014Applicant: Eli Lilly and CompanyInventors: Julian Davies, Ling Liu, Jirong Lu
-
Patent number: 8623365Abstract: The present invention encompasses isolated antibodies, or fragments thereof, that are humanized variants of murine antibody 266 which employ complementarity determining regions derived from murine antibody 266. The variant antibodies are useful for treatment or prevention of conditions and diseases associated with A?, including Alzheimer's disease, Down's syndrome, cerebral amyloid angiopathy, mild cognitive impairment, and the like.Type: GrantFiled: December 21, 2011Date of Patent: January 7, 2014Assignee: Applied Molecular Evolution, Inc.Inventors: Julian Davies, Ying Tang, Jeffry Dean Watkins
-
Publication number: 20130273071Abstract: The present invention provides novel antibodies that immunospecifically bind to an IL-9 polypeptide and compositions comprising said antibodies. The present invention also provides methods and compositions preventing, treating, managing, and/or ameliorating diseases and disorders associated with aberrant expression and/or activity of IL 9 or IL-9 receptor or subunits thereof, autoimmune diseases, inflammatory diseases, proliferative diseases, and infections comprising administration of one or more antibodies thereof that immunospecifically bind to an IL-9 polypeptide. The invention also encompasses methods and compositions for diagnosing, monitoring, and prognosing these disorders. The present invention further relates to articles of manufacture and kits comprising antibodies that immunospecifically bind to an IL-9 polypeptide.Type: ApplicationFiled: June 6, 2013Publication date: October 17, 2013Inventors: Jennifer Lynne Reed, Herren Wu, Ying Tang, Julian Davies, Jeffry Watkins
-
Patent number: 8530414Abstract: The present invention relates to antibodies to proprotein convertase subtilisin/kexin type 9 (PCSK9), or antigen-binding fragments thereof, compositions comprising such PCSK9 antibodies or antigen-binding fragments, and methods of using the same for the treatment of hyperlipidemia or hypercholesterolemia.Type: GrantFiled: September 12, 2012Date of Patent: September 10, 2013Assignee: Eli Lilly and CompanyInventors: Julian Davies, Ryan James Darling, Barrett Allan
-
Patent number: 8481037Abstract: The present invention provides novel antibodies that immunospecifically bind to an IL-9 polypeptide and compositions comprising said antibodies. The present invention also provides methods and compositions preventing, treating, managing, and/or ameliorating diseases and disorders associated with aberrant expression and/or activity of IL 9 or IL-9 receptor or subunits thereof, autoimmune diseases, inflammatory diseases, proliferative diseases, and infections comprising administration of one or more antibodies thereof that immunospecifically bind to an IL-9 polypeptide. The invention also encompasses methods and compositions for diagnosing, monitoring, and prognosing these disorders. The present invention further relates to articles of manufacture and kits comprising antibodies that immunospecifically bind to an IL-9 polypeptide.Type: GrantFiled: January 14, 2011Date of Patent: July 9, 2013Assignee: MedImmune, LLCInventors: Jennifer Lynne Reed, Herren Wu, Ying Tang, Julian Davies, Jeffry Watkins
-
Publication number: 20130071405Abstract: The present invention relates to antibodies to proprotein convertase subtilisin/kexin type 9 (PCSK9), or antigen-binding fragments thereof, compositions comprising such PCSK9 antibodies or antigen-binding fragments, and methods of using the same for the treatment of hyperlipidemia or hypercholesterolemia.Type: ApplicationFiled: September 12, 2012Publication date: March 21, 2013Applicant: ELI LILLY AND COMPANYInventors: Julian Davies, Ryan James Darling, Barrett Allan
-
Patent number: 8398974Abstract: Provided are monoclonal antibodies, antigen-binding fragments thereof, and combinations of the foregoing, that bind to, and inhibit the activity of, c-Met, and that are effective in treating cancers and other diseases, disorders, or conditions where pathogenesis is mediated by c-Met.Type: GrantFiled: June 25, 2012Date of Patent: March 19, 2013Assignee: Eli Lilly and CompanyInventors: Julian Davies, Ling Liu, Jirong Lu, Peter Edward Vaillancourt, Mark Andrew Wortinger, Wei Zeng
-
Publication number: 20120263723Abstract: Provided are monoclonal antibodies, antigen-binding fragments thereof, and combinations of the foregoing, that bind to, and inhibit the activity of, c-Met, and that are effective in treating cancers and other diseases, disorders, or conditions where pathogenesis is mediated by c-Met.Type: ApplicationFiled: June 25, 2012Publication date: October 18, 2012Applicant: ELI LILLY AND COMPANYInventors: Julian Davies, Ling Liu, Jirong Lu, Peter Edward Vaillancourt, Mark Andrew Wortinger, Wei Zeng
-
Patent number: 8217148Abstract: Provided are monoclonal antibodies, antigen-binding fragments thereof, and combinations of the foregoing, that bind to, and inhibit the activity of, c-Met, and that are effective in treating cancers and other diseases, disorders, or conditions where pathogenesis is mediated by c-Met.Type: GrantFiled: November 18, 2009Date of Patent: July 10, 2012Assignee: Eli Lilly and CompanyInventors: Julian Davies, Ling Liu, Jirong Lu, Peter Edward Vaillancourt, Mark Andrew Wortinger, Wei Zeng
-
Publication number: 20120114560Abstract: The present invention encompasses isolated antibodies, or fragments thereof, that are humanized variants of murine antibody 266 which employ complementarity determining regions derived from murine antibody 266. The variant antibodies are useful for treatment or prevention of conditions and diseases associated with A?, including Alzheimer's disease, Down's syndrome, cerebral amyloid angiopathy, mild cognitive impairment, and the like.Type: ApplicationFiled: December 21, 2011Publication date: May 10, 2012Applicant: APPLIED MOLECULAR EVOLUTION, INC.Inventors: Julian DAVIES, Ying TANG, Jeffry Dean WATKINS
-
Publication number: 20120109097Abstract: The present invention provides novel antibodies that immunospecifically bind to an IL-9 polypeptide and compositions comprising said antibodies. The present invention also provides methods and compositions preventing, treating, managing, and/or ameliorating diseases and disorders associated with aberrant expression and/or activity of IL 9 or IL-9 receptor or subunits thereof, autoimmune diseases, inflammatory diseases, proliferative diseases, and infections comprising administration of one or more antibodies thereof that immunospecifically bind to an IL-9 polypeptide. The invention also encompasses methods and compositions for diagnosing, monitoring, and prognosing these disorders. The present invention further relates to articles of manufacture and kits comprising antibodies that immunospecifically bind to an IL-9 polypeptide.Type: ApplicationFiled: January 14, 2011Publication date: May 3, 2012Applicant: MEDIMMUNE, LLCInventors: Jennifer Lynne Reed, Herren Wu, Ying Tang, Julian Davies, Jeffry D. Watkins
-
Patent number: 8153125Abstract: The present invention relates to CD20 binding molecules and nucleic acid sequences encoding CD20 binding molecules. In particular, the present invention relates to CD20 binding molecules with a high binding affinity, and a low dissociation rate, with regard to human CD20. Preferably, the CD20 binding molecules of the present invention comprise light and/or heavy chain variable regions with fully human frameworks (e.g. human germline frameworks).Type: GrantFiled: May 20, 2004Date of Patent: April 10, 2012Assignee: Applied Molecular Evolution, Inc.Inventors: Jeffry D. Watkins, Julian Davies, David M. Marquis, Barrett W Allan, Brian Ondek
-
Patent number: 8128927Abstract: TGF-beta 1 binding compositions and reagents related thereto are provided. Methods of using such compositions for therapeutic purpose are also provided.Type: GrantFiled: October 15, 2009Date of Patent: March 6, 2012Assignee: Eli Lilly and CompanyInventors: Julian Davies, Craig Duane Dickinson, David Matthew Marquis, Ying Tang, Peter Edward Vaillancourt
-
Patent number: 8105597Abstract: The present invention encompasses isolated antibodies, or fragments thereof, that are humanized variants of murine antibody 266 which employ complementarily determining regions derived from murine antibody 266. The variant antibodies are useful for treatment or prevention of conditions and diseases associated with A?, including Alzheimer's disease. Down's syndrome, cerebral amyloid angiopathy, mild cognitive impairment, and the like.Type: GrantFiled: July 17, 2009Date of Patent: January 31, 2012Assignee: Applied Molecular Evolution, Inc.Inventors: Julian Davies, Ying Tang, Jeffry Dean Watkins
-
Patent number: 8066995Abstract: Anti-myostatin antibodies are identified that are characterized as having high affinity and may be chimeric, humanized or fully human antibodies, immunoconjugates of the antibodies or antigen-binding fragments thereof. The antibodies of the invention are useful for increasing muscle mass, increasing bond density, or for the treatment of various disorders in mammalian and avian species, X17251.Type: GrantFiled: November 3, 2009Date of Patent: November 29, 2011Assignee: Eli Lilly and CompanyInventors: Julian Davies, Bryan Edward Jones, Andrew Ihor Korytko, Pamela Jean Mitchell, Rosamund Carol Smith, Linda O'Bryan (Nee Tobias), Rong Wang